Director Charles W. Newton proposes selling 551 shares of Keros Therapeutics (KROS).
Keros Therapeutics director Charles W. Newton has filed a Form 144 proposing to sell 551 common shares of KROS, valued at $5,521.02, with an approximate sale date of November 17, 2026. These shares were acquired as restricted stock units on November 15, 2026, and a Rule 10b5-1 plan was adopted on March 12, 2026. Newton also reported a prior sale of 551 common shares on August 18, 2026.
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Consensus Target Price of $20.00 According to Brokerages
Keros Therapeutics, Inc. (NASDAQ:KROS) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $20.00. The company recently reported strong quarterly earnings, beating estimates with $0.70 EPS and $40.01 million in revenue. Keros Therapeutics also authorized a $5 million share repurchase plan, leading to a 12.8% increase in its stock price.
Keros Therapeutics approves $5M share buyback program By Investing.com
Keros Therapeutics, Inc. (NASDAQ:KROS) has announced that its Board of Directors approved a $5 million share repurchase program for the company's common stock. This authorization follows a $20 million development milestone payment received from Takeda Pharmaceuticals U.S.A., Inc. for their license agreement concerning elritercept. The program allows Keros management to repurchase shares from time to time, with the timing and amount dependent on market conditions and other factors.
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
Keros Therapeutics, Inc. announced that its Board of Directors has approved a new $5 million share repurchase program for the company's common stock. This decision follows the receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc., related to the ELRiSE MF clinical trial. The program allows management to repurchase shares in the open market, with timing and amount dependent on market conditions and other factors.
Keros Therapeutics approves $5M share buyback program By Investing.com
Keros Therapeutics, Inc. (NASDAQ:KROS) has announced that its Board of Directors approved a $5 million share repurchase program for its common stock. This decision follows the company's receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc., triggered by the first patient dosing in the ELRiSE MF clinical trial. The program grants Keros management the authority to repurchase shares in the open market, with the timing and amount subject to various factors including market conditions and contractual limitations.
Keros Therapeutics launches $5M share buyback program
Keros Therapeutics (KROS) announced a new $5 million share repurchase program. The timing and amount of repurchases will be influenced by various factors, including the company's stock market price, economic conditions, and contractual limitations. This program allows the company flexibility in buying back its common stock.
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
Keros Therapeutics (Nasdaq: KROS) announced that its Board of Directors has approved a new $5 million share repurchase program for its common stock. This decision follows the receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A. Inc., triggered by the dosing of the first patient in the ELRiSE MF clinical trial. The timing and amount of repurchases will depend on market conditions and other factors, and the program does not obligate the company to purchase any specific amount of shares.
Keros Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 94% Upside
Keros Therapeutics, Inc. (KROS) has seen its average 12-month price target increased to $20 by analysts, with individual forecasts ranging from $16 to $25 per share. This updated target suggests a potential upside of approximately 94% from its Nov. 13 closing price. The consensus rating from 7 covering analysts remains "Buy," comprising 4 Buys and 3 Holds.
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
Keros Therapeutics announced an additional $5 million share repurchase authorization following a $20 million development milestone payment from Takeda Pharmaceuticals for elritercept. This program allows Keros to repurchase its common stock based on market conditions and other factors, but does not obligate the company to buy a specific amount. The company is a clinical-stage biopharmaceutical firm focused on developing therapies for disorders linked to dysfunctional TGF-ß family protein signaling.
Avoiding Lag: Real-Time Signals in (KROS) Movement
This article provides a real-time analysis of Keros Therapeutics Inc. (NASDAQ: KROS), highlighting a near-term neutral sentiment amidst mid and long-term weakness. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels.
Keros Therapeutics (NASDAQ:KROS) Upgraded at Zacks Research
Zacks Research has upgraded Keros Therapeutics (NASDAQ:KROS) to a "strong buy" rating, noting the company's strong quarterly performance where it significantly beat EPS and revenue estimates. The firm also authorized a $5 million share-repurchase plan. Despite an overall "Moderate Buy" consensus from analysts with an average price target of $21.40, Keros still faces some uncertainty regarding its path to profitability.
Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Wall Street Zen
Keros Therapeutics (NASDAQ:KROS) has been upgraded from a "strong sell" to a "hold" rating by Wall Street Zen, aligning with the broader analyst consensus and an average price target of $21.40. The company recently reported strong quarterly earnings, significantly beating analyst estimates with $0.70 per share and revenue of $40.01 million. Keros Therapeutics also announced a $5 million share repurchase program, indicating management's belief that the stock is undervalued.
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Beats Estimates By $1.66 EPS
Keros Therapeutics (NASDAQ:KROS) reported strong quarterly earnings, beating analyst estimates with an EPS of $0.70 compared to an expected loss of $0.96, and revenue of $40.01 million against a forecast of $14.76 million. Despite the positive results, shares fell $1.38 to $9.45, nearing a 12-month low. The company's board also authorized a $5 million share buyback program.
Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates
Keros Therapeutics (KROS) reported Q3 earnings of $0.7 per share, significantly surpassing the Zacks Consensus Estimate of a loss of $0.96 per share, and revenues of $40.01 million, beating estimates by 197.47%. Despite these strong quarterly results, the company's shares have fallen 46.8% year-to-date, contrasting with the S&P 500's gain, and currently hold a Zacks Rank #3 (Hold). Investors are now looking to future earnings calls for management's commentary and estimate revisions to gauge the stock's future performance.
A $259.5 million cash balance is expected to fund Keros' operations into the second half of 2028.
Keros Therapeutics reported a Q3 2026 net income of $14.2 million, a reversal from a loss in the previous year, driven by a significant increase in license revenue to $40 million. The company announced progress in its clinical pipeline, including the first patient dosed in a Phase 2 Duchenne muscular dystrophy trial for rinvatercept and the nomination of KER-206 for bone disorders. Keros also confirmed a cash and cash equivalents balance of $259.5 million, projected to fund operations into the second half of 2028.
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Keros Therapeutics reported significant progress in its clinical and nonclinical development pipeline, including dosing the first patient in a Phase 2 trial for rinvatercept in Duchenne muscular dystrophy patients and nominating KER-206 for further investigation into bone remodeling. The company also announced a net income of $14.2 million for the third quarter of 2026, driven by a licensing agreement with Takeda, and expects its cash runway to extend into the second half of 2028.
Responsive Playbooks and the KROS Inflection
This article provides an in-depth analysis of Keros Therapeutics Inc. (NASDAQ: KROS), highlighting near-term weak sentiment that may signal a resumption of long-term weakness. It identifies a strong risk-reward short setup and outlines three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis for near-term, mid-term, and long-term horizons, indicating prevailing weak sentiment.
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Keros Therapeutics (NASDAQ:KROS) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Hold" with a target price of $20.50. KROS shares opened at $11.04, near its 52-week low, after reporting a quarterly loss of $1.45 per share, missing consensus estimates. The company has also approved a $5 million stock buyback program, indicating management's belief that the stock may be undervalued.
BlackRock reports a Keros Therapeutics (KROS) stake with sole voting power over 1.58M shares.
BlackRock Portfolio Management LLC has reported a 9.1% beneficial ownership stake in Keros Therapeutics, Inc. (KROS), totaling 1,813,870 shares as of September 30, 2026. This position includes sole voting power over 1,575,150 shares and sole dispositive power over all 1,813,870 shares. The filing indicates that while various persons may direct dividends or sale proceeds, no single individual's interest exceeds 5% of the outstanding common stock.
Weekly Recap: Milestone payment and Phase II rinvatercept DMD trial
Keros Therapeutics (NASDAQ:KROS) announced it received a milestone payment from Takeda, extending its cash runway into the second half of 2028. The company also initiated a Phase II open-label trial for rinvatercept in Duchenne muscular dystrophy, with DEXA data expected in the first half of 2027. This follows a 2025 corporate reset where KROS returned $375 million of capital.
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
Keros Therapeutics is reorienting its pipeline, focusing on rinvatercept for neuromuscular diseases like Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). The company anticipates initial safety and tissue-level data for rinvatercept in DMD in the first half of 2027, with plans for a placebo-controlled study to demonstrate functional benefits. Keros also expects to begin a Phase II trial for rinvatercept in ALS in 2027, aiming to preserve skeletal muscle and delay symptom progression.
Avoiding Lag: Real-Time Signals in (KROS) Movement
This article provides an in-depth analysis of Keros Therapeutics Inc. (NASDAQ: KROS) movement, highlighting divergent sentiment across different time horizons and testing resistance levels. It details AI-generated institutional trading strategies for long, breakout, and short positions, complete with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strengths, support, and resistance levels to help traders navigate choppy conditions and optimize risk management.
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Rated "Hold" by Sell-Side Brokerages
Keros Therapeutics (NASDAQ:KROS) has received a consensus "Hold" rating from nine sell-side brokerages, with an average 12-month price target of $20.50. The company reported a quarterly loss of $1.45 per share, missing analyst estimates, and announced a $5 million share-repurchase program. Despite institutional ownership of 71.56%, insiders have been selling shares in recent months.
Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to Strong Sell
Keros Therapeutics (NASDAQ:KROS) was downgraded by Wall Street Zen from a "sell" to a "strong sell" rating, despite a broader analyst consensus remaining "hold" with a $20.50 target price. The company's stock opened at $11.28, near its 52-week low, and reported a quarterly loss of $1.45 per share, missing analyst estimates. Keros Therapeutics also authorized a $5 million share-repurchase program and currently has 71.56% of its stock owned by institutional investors.
Keros Therapeutics, Inc. Estimates – NASDAQ:KROS
This article provides financial estimates and actuals for Keros Therapeutics, Inc. (NASDAQ: KROS) on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.
Keros Therapeutics Drops To US$10.66, Yet Insiders May Have Sold Too Early
Keros Therapeutics' stock (NASDAQ: KROS) has fallen 11% recently, dropping to US$10.66. Despite this, insiders who sold US$484k worth of stock over the past year might have sold too early, as their average selling price of US$13.86 was still lower than the current price. The article highlights significant insider selling over the last three months but notes that a large sale by the President was above the current share price, potentially not indicating a lack of confidence.
Discipline and Rules-Based Execution in KROS Response
Keros Therapeutics Inc. (NASDAQ: KROS) is showing stable neutral readings in shorter horizons, potentially indicating an easing of a long-term weak bias. An exceptional 89.7:1 risk-reward short setup is identified, targeting a 22.8% downside against a 0.3% risk. Three distinct AI-generated trading strategies are provided for different risk profiles, including position, momentum breakout, and risk hedging strategies.
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen
Wall Street Zen has upgraded Keros Therapeutics (NASDAQ:KROS) from a "strong sell" to a "sell" rating, while the broader analyst consensus remains "Hold" with an average price target of $20.50. The company reported a wider-than-expected quarterly loss of $1.45 per share, missing estimates. Keros Therapeutics also announced a $5 million stock buyback program, and institutional investors own a significant portion of its shares.
How (KROS) Movements Inform Risk Allocation Models
This article analyzes Keros Therapeutics Inc. (NASDAQ: KROS) movements, highlighting weak near-term and long-term sentiment with a neutral mid-term outlook. It identifies an exceptional 89.7:1 risk-reward short setup and provides three institutional trading strategies tailored for different risk profiles and holding periods, based on AI model analysis. The strategies include position, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels.
Keros Therapeutics Inc (KROS-Q) Stock Price and News
This article provides stock information and recent news for Keros Therapeutics Inc (KROS-Q), a clinical-stage biopharmaceutical company focused on hematological and musculoskeletal disorders. It highlights recent news about their drug trials, financial updates, analyst ratings, and executive changes. The company's pipeline includes KER-050, KER-047, and KER-012, all in clinical stages.
Keros Therapeutics to receive $20M milestone from Takeda By Investing.com
Keros Therapeutics is set to receive a $20 million milestone payment from Takeda after the first patient was dosed in the ELRiSE MF clinical trial. This payment is part of a global license agreement initiated in January 2025, which included a $200 million upfront payment and potential future milestones exceeding $1.1 billion. Keros plans to distribute 25% of the net cash proceeds from this milestone to its stockholders.
Keros Therapeutics, Inc. (KROS) Stock Price, News, Quote & History
Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company focused on developing therapies for disorders related to dysfunctional signaling of the TGF-beta family of proteins. The company's stock closed at $11.36, with a year-to-date return of -44.20%. Analysts have an average target price of $19.83 for KROS.
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Keros Therapeutics is set to receive a $20 million development milestone payment from its partner Takeda following the dosing of the first patient in the ELRiSE MF clinical trial for elritercept, a drug designed to treat myelofibrosis with anemia. This payment is part of a larger global license agreement that could see Keros receive over $1.1 billion in milestones and royalties. Keros plans to distribute 25% of the net cash proceeds from this milestone payment to its stockholders.
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics has dosed the first patient in a Phase II study for rinvatercept, its lead pipeline candidate for Duchenne muscular dystrophy (DMD). The study aims to evaluate the safety and tolerability of rinvatercept in late-ambulatory and early non-ambulatory DMD patients, with initial data expected in the first half of 2027. Keros is also developing elritercept for cytopenias, having recently received a $20 million milestone payment from Takeda for its Phase III ELRiSE MDS study.
Keros Therapeutics to receive $20M milestone from Takeda
Keros Therapeutics (NASDAQ:KROS) announced it is set to receive a $20 million development milestone payment from its partner Takeda. This payment follows the dosing of the first patient in the ELRiSE MF clinical trial, a Phase 3 study for patients with myelofibrosis and anemia. The milestone is part of a global license agreement that could yield Keros over $1.1 billion in development, commercial, and sales milestones, in addition to royalties on net sales.
Keros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 Trial
Keros Therapeutics is set to receive a $20 million milestone payment from Takeda after the first patient was dosed in the Phase 3 ELRiSE MF clinical trial for elritercept, a treatment for myelofibrosis and anemia. The global license agreement with Takeda includes potential milestone payments exceeding $1.1 billion and tiered royalties on sales, with Keros planning to distribute 25% of the net cash proceeds from this milestone to its stockholders. Elritercept is Keros' most advanced product candidate and is designed to address low blood cell counts.
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Keros Therapeutics has announced the first patient has been dosed in its Phase 2 clinical trial for rinvatercept, a novel therapeutic designed to treat Duchenne muscular dystrophy (DMD). Rinvatercept aims to modulate key regulators of muscle and bone biology to improve muscle regeneration and strength. Initial data from the trial is expected in the first half of 2027, representing a significant step in addressing the ongoing need for DMD treatment options.
Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
Keros Therapeutics anticipates a $20 million milestone payment from Takeda. This payment is related to a development milestone, as announced by Keros Therapeutics on Tuesday.
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages
Keros Therapeutics (NASDAQ:KROS) has an average target price of $20.50 from brokerages, with analysts giving it a "Hold" consensus based on four buy, four hold, and one sell rating. The company recently reported quarterly adjusted earnings of -$1.45 per share, missing consensus, and has authorized a $5 million stock buyback. Institutional investors hold 71.56% of the stock, while insiders have sold approximately $55,000 worth of shares in the last three months.
The first patient has received a drug being tested for Duchenne muscular dystrophy. Initial data are expected in 2027.
Keros Therapeutics has dosed the first patient in its Phase 2 clinical trial evaluating rinvatercept for Duchenne muscular dystrophy (DMD). The company anticipates initial trial data to be available in the first half of 2027. Rinvatercept is designed to modulate proteins involved in muscle and bone biology, and this trial aims to assess its potential impact on both ambulatory and non-ambulatory DMD patients.
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Keros Therapeutics has initiated a Phase 2 clinical trial for rinvatercept in patients with Duchenne muscular dystrophy (DMD), with the first patient successfully dosed. Rinvatercept is designed to modulate key regulators of muscle and bone biology by acting as a ligand trap for myostatin and activin A, aiming to improve muscle regeneration, strength, and overall bone health. Initial data from this trial is anticipated in the first half of 2027, representing a significant step in Keros's neuromuscular development strategy.
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Keros Therapeutics announced the first patient has been dosed in its Phase 2 clinical trial for rinvatercept, a novel therapeutic designed to treat Duchenne muscular dystrophy (DMD). The drug aims to modulate key regulators of muscle and bone biology, with initial data expected in the first half of 2027. This open-label, multi-cohort basket trial will assess the safety, tolerability, pharmacokinetics, and functional improvements of rinvatercept in both ambulatory and non-ambulatory DMD patients.
Keros Therapeutics, Inc. (KROS) Stock Analysis: A Biotech Gem with 74.59% Upside Potential
Keros Therapeutics, Inc. (KROS) is highlighted as a compelling investment opportunity in the biotechnology sector, boasting a potential upside of 74.59%. The company, a clinical-stage biopharmaceutical firm, is developing therapeutics for disorders related to transforming growth factor-beta family proteins. Despite not yet being profitable, its innovative pipeline, strategic collaborations with Hansoh and Takeda, and favorable analyst ratings position it as a noteworthy stock for long-term growth-oriented investors.
Keros Therapeutics, Inc. SEC Filing (Sep 17, 2026)
This article reports on an SEC filing by Keros Therapeutics, Inc. (KROS) related to the effectiveness of a Shelf Registration Statement (Form S-3) on September 16, 2026. The filing indicates a neutral impact and sentiment according to AI analysis, and the article also provides recent news and SEC filing history for the company.
Keros Therapeutics director Bienaime buys $10,270 in shares
Jean Jacques Bienaime, a director at Keros Therapeutics, Inc. (NASDAQ:KROS), recently purchased 1,000 shares of the company's common stock for $10,270. This transaction, executed via a Rule 10b5-1 trading plan, increased his beneficial ownership to 19,592 shares. The purchase occurred while KROS trades near its 52-week low, with InvestingPro analysis suggesting the stock is undervalued despite burning cash.
(KROS) Volatility Zones as Tactical Triggers
This article analyzes Keros Therapeutics Inc. (NASDAQ: KROS) through volatility zones, identifying stable neutral readings in shorter horizons and a mid-channel oscillation pattern. It highlights an exceptional 95.3:1 risk-reward setup targeting a 29.6% gain, alongside neutral sentiment. The analysis provides specific institutional trading strategies for long, breakout, and short positions, based on AI-generated signals and multi-timeframe analysis.
Bank of New York Mellon Corp Takes $1.11 Million Position in Keros Therapeutics, Inc. $KROS
Bank of New York Mellon Corp has acquired a new position in Keros Therapeutics, Inc., purchasing 103,339 shares valued at approximately $1.11 million. This comes as Keros Therapeutics reported a quarterly loss worse than anticipated and authorized a $5 million share repurchase program. Analysts currently maintain a "Hold" rating on the stock with an average price target of $20.50.
Share Buyback Program Approved by Keros Therapeutics (NASDAQ:KROS) Board of Directors
Keros Therapeutics' Board of Directors has approved a $5 million share repurchase program, authorizing the company to buy back up to 2.3% of its outstanding shares. This decision comes as KROS shares trade near the midpoint of their 52-week range, despite the company reporting a wider-than-expected quarterly loss. Analyst sentiment for Keros Therapeutics remains mixed, with an average "Hold" rating and a price target of $20.50, though some recent targets have been lowered.
Keros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares.
Keros Therapeutics, Inc. has announced a share repurchase program, authorizing the buyback of up to $5 million worth of its common stock. This decision was published on September 8, 2026, at 04:03 pm EDT. The biotechnology company focuses on developing therapeutics for disorders related to dysfunctional TGF-beta family proteins.
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Keros Therapeutics has announced a $5 million share repurchase program for its common stock. This authorization follows the receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. The timing and amount of repurchases will depend on market conditions and other factors, and the program can be modified or discontinued at any time.